Skip to main content
SpringerLink
Log in

Immunotherapy of a Murine T Cell Lymphoma Localized to the Brain

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Mouse YC8 T cell lymphoma was used as a model to determine whether an effective immunotherapy procedure could be devised for the treatment of lymphoma localized to the brain. Implantation of 5 × 104 YC8 cells into the left cerebral hemisphere induced rapid loss of the animal's body weight. Severe loss of weight and early deaths were observed in the untreated control group. Although resistance can be conferred to the brain by immunization of naive BALB/c mice, adoptive chemoimmunotherapy procedures were surprisingly not effective in inducing remissions in animals with lymphoma confined to the brain. Even passive transfer of effector cells from immunized, tumor resistant donor animals combined with systemic IL-2 treatment did not impart resistance to recipients with brain tumors. However, regression of the intracranial tumor and apparent cures could be accomplished, when ex vivo cultured effector cells were transferred intravenously.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Ling SM, Roach M, Larson DA, Wara WM: Radiotherapy of primary CNS lymphoma in patients with and without human immunodeficiency virus. Canc 73: 2570-2582, 1994

    Google Scholar 

  2. Cote TR, Manns A, Jardu CR, Yellin FJ, Hartge P: Epidemiology of brain lymphoma among people with our without acquired immunodeficiency syndrome. J Natl Canc Inst 88: 675-679, 1996

    Google Scholar 

  3. Grant JW, Isaacson PG: Primary CNS lymphoma. Brain Pathol 2: 97-109, 1992

    Google Scholar 

  4. Goldstein JD, Dickson DW, Moser FG, Hirschfeld AD, Freeman K, Lena JF, Kaplan B, Davis L: Primary central nervous system lymphoma in acquired immunodeficiency syndrome. Canc 67: 2756-2765, 1991

    Google Scholar 

  5. Remick SC, Diamond C, Migliozzi JA, Solis O, Wagner H, Haase RF, Ruckdeschel JC: Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome. Med 69: 345-360, 1990

    Google Scholar 

  6. Marks WJ, McArthur JC, Royal W, Kumar AJ, Erozan Y, Herman C, Uematsu S: Intracranial mass lesions in AIDS: Diagnosis and response to therapy. Neurol 39: 380, 1989

    Google Scholar 

  7. Fine HA, Mayer RJ: Primary CNS lymphoma. Ann Int Med 119: 1093-1104, 1993

    Google Scholar 

  8. Saito M, Nanjo M, Kataoka M: Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice. Cancer Res 48: 4163-4167, 1988

    Google Scholar 

  9. Greenberg PD, Kern DE, Cheever MA: Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1C, 2-T-cells. J Exp Med 16l: 1122-1134, 1985

    Google Scholar 

  10. Awwad M, North RJ: Radiosensitive barrier to T-cell mediated adoptive immunotherapy of established tumors. Cancer Res 50: 2228-2233, 1990

    Google Scholar 

  11. Parmiani G, Sensi M, Carbone G, Colombo M, Pierotti M, Ballinari D, Hilers J, Hilkens J: Cross-reactions between tumor cells and allogeneic normal tissues: Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice. Int J Canc 29: 323-332 1982

    Google Scholar 

  12. Hiramoto RN, Hiramoto NS, Rish ME, Soong S-J, Miller DM, Ghanta VK: Role of immune cells in the Pavlovian conditioning of specific resistance to cancer. Int J Neurosci 59: 101-117, 1991

    Google Scholar 

  13. Ghanta V, Hiramoto N, Soong S-J, Miller D, Hiramoto R: A multiple modality approach combining the effect of conditioning with adoptive chemoimmunotherapy. Int J Neurosci 71: 251-265, 1993

    Google Scholar 

  14. Hiramoto RN, Ghanta VK, Soong, S-J, Hiramoto NS: Use of an allogeneic antigen to induce resistance and regression of an autologous tumor. J Immunother 15: 202-211, 1994

    Google Scholar 

  15. Sano K: The future role of neurosurgery in the care of cerebral tumors. Neurol Rev 9: 3-22, 1986

    Google Scholar 

  16. Merchant RE, Ellison MD, Young HF: Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes: A review of preclinical and clinical investigation. J Neuro-Oncol 8: 173-188, 1990

    Google Scholar 

  17. Merchant RE, Merchant LH, Cook SH, McVicar DW, Young HF: Intralesional infusion of lymphokine activated killer (LAK) cells and recombinant interleukin-2 for the treatment of patients with malignant brain tumor. Neurosurg 23(6): 725-732, 1988

    Google Scholar 

  18. Takai N, Tanaka R, Yoshida S, Hara N, Saito T: In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells. Canc Res 48: 2047-2052, 1988

    Google Scholar 

  19. Ogasawara M, Rosenberg SA: Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with γ-interferon genes. Canc Res 53: 3561-3568, 1993

    Google Scholar 

  20. Tepper RI, Pattengale PK, Leder P: Murine interleukin 4 displays potent anti-tumor activity in vivo. Cell 57: 503-512, 1989

    Google Scholar 

  21. Lae Y, Bigner DD: Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human glioma. Neurol Clin 3: 901-917, 1985

    Google Scholar 

  22. Yannelli JR, Crumpacker DB, Good RW, Findell CD, Paston R, Horten S, Maleckar JR, Oldham RK: Use of anti-CD3 monoclonal antibody in the generation of effector cells from solid human tumors for use in cancer biotherapy. J Immunol Meth 130: 91-100, 1990

    Google Scholar 

  23. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE: Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863-1874, 1989

    Google Scholar 

  24. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Lineham WM, Robertson CN, Lee RE, Rubi JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 880-897, 1987

    Google Scholar 

  25. Sensi M, Orosz CG, Bach FH: Alloantigen induced cytotoxcity against syngeneic tumor cells: analysis at the clonal level. J Immunol 132: 3218-3225, 1984

    Google Scholar 

  26. Sensi ML, Parenza M, Parmiani G: Alloreactivity and tumor antigens: Generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells. J Natl Canc Inst 70: 291-297, 1983

    Google Scholar 

  27. Matsumura M, Fremont DH, Peterson PA, Wilson IA: Emerging principles for the recognition of peptide antigens by MHC class I molecules. Sci 257: 927-934, 1992

    Google Scholar 

  28. Baxevanis CN, Papamichail M: Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy. Crit Rev Oncol-Hematol 16: 157-179, 1994

    Google Scholar 

  29. Ghanta VK, Hiramoto NS, Solvason HB, Soong S-J, Hiramoto RN: Conditioning: A new approach to immunotherapy. Canc Res 50: 4295-4299, 1990

    Google Scholar 

  30. Gazzinelli R, Xu Y, Hieny S, Cheever A, Sher A: Simultaneous depletion of CD4C and CD8C T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. J Immunol 149: 175-180, 1992

    Google Scholar 

  31. Chang AE, Yoshizawa H, Sakai S, Cameron MJ, Sondak VK, Shu S: Clinical observations on adoptive immunotherapy with vaccine-primed T-Iymphocytes secondarily sensitized to tumor in vitro. Canc Res 53: 1043-1050, 1993

    Google Scholar 

  32. Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL: Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro sensitized vaccine draining lymph node lymphocytes. Canc Res 53: 4745-4749, 1993

    Google Scholar 

  33. Tracey KJ, Morgello S, Koplin B, Fahey III TJ, Fox J, Aledo A, Mangue KR, Cerami A: Metabolic effects of cachectin, tumor necrosis factor are modified by site of production. J Clin Invest 86: 2014-2024, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, Department of Biology, University of Alabama at Birmingham, Birmingham, AL, USA

    Vithal K. Ghanta

  2. Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA

    Nancy S. Hiramoto & Raymond N. Hiramoto

  3. Division of Neurosurgery, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA

    G.Y. Gillespie

  4. School of Nursing, University of Alabama at Birmingham, Birmingham, AL, USA

    Dorothy K. Gauthier

Authors
  1. Vithal K. Ghanta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nancy S. Hiramoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G.Y. Gillespie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dorothy K. Gauthier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raymond N. Hiramoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghanta, V.K., Hiramoto, N.S., Gillespie, G. et al. Immunotherapy of a Murine T Cell Lymphoma Localized to the Brain. J Neurooncol 47, 1–10 (2000). https://doi.org/10.1023/A:1006475516746

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006475516746

Search

Navigation